VANDA PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
VANDA PHARMACEUTICALS INC. (VNDA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -4.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2025-02-14
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -4.50%, a 126.16% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 17.20%, a 82.98% increase from fiscal 2022.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 9.40%, a 261.54% increase from fiscal 2021.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was 2.60%, a 52.94% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2024-12-31 | -4.50% 10-K · filed 2025-02-14 |
| 2023-12-31 | 17.20% 10-K · filed 2025-02-14 |
| 2022-12-31 | 9.40% 10-K · filed 2025-02-14 |
| 2021-12-31 | 2.60% 10-K · filed 2024-02-08 |
| 2020-12-31 | 1.70% 10-K · filed 2023-02-09 |
| 2019-12-31 | 2.70% 10-K · filed 2022-02-24 |
| 2018-12-31 | 3.10% 10-K · filed 2021-02-11 |
| 2017-12-31 | 8.10% 10-K · filed 2020-02-26 |
| 2016-12-31 | 0.00% 10-K · filed 2019-02-19 |
| 2015-12-31 | -5.70% 10-K · filed 2018-02-15 |
| 2014-12-31 | 1.10% 10-K · filed 2017-02-17 |
| 2013-12-31 | 1.20% 10-K · filed 2016-02-12 |
| 2012-12-31 | 0.00% 10-K · filed 2015-03-13 |
| 2010-12-31 | 2.50% 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |